Showing 3521-3530 of 4764 results for "".
- Research Substantiates Psoriasis/Non-alcoholic Fatty Liver Disease Linkhttps://practicaldermatology.com/news/research-substantiates-psoriasisnon-alcoholic-fatty-liver-disease-link/2460174/The severity of psoriasis is related to the severity of non-alcoholic fatty liver disease (NAFLD), according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Patients with psoriasis and NAFLD had more severe hepatic damage if they had a higher s
- EADV News: Diet Linked to Acnehttps://practicaldermatology.com/news/eadv-news-diet-linked-to-acne/2460172/Consuming dairy products, sweets, soda or juice daily may increase risk for developing acne, according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. The study, which included of more than 6,700 participants across six countries in North
- Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/galderma-advances-phase-3-clinical-study-with-nemolizumab-in-moderate-to-severe-atopic-dermatitis/2460171/Galderma has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate to severe atopic dermatitis. This randomized, double-blinded, placebo-controlled study will assess the efficacy and safety of nemolizumab in subjec
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Neutrogena’s Newest Collection Addresses Dull, Uneven Skinhttps://practicaldermatology.com/news/neutrogenas-newest-collection-addresses-dull-uneven-skin/2460157/Nearly two-thirds (66 percent) of U.S. millennial women age 23-38 have noticed a shift in their skin's brightness, according to a poll of more 1,100 U.S. women aged 18 and older sponsored by Neutrogena. Neutrogena’s new four-part collection,
- International Council Of Dermatologists Introduces New Method Of Determining Psoriasis Severityhttps://practicaldermatology.com/news/international-council-of-dermatologists-introduces-new-method-of-determining-psoriasis-severity/2460155/A new method to classify psoriasis severity can determine the appropriate course of treatment, according to a consensus paper by the International Psoriasis Council (IPC). The paper is published in the Journal of the American Academy of Dermatology. “There's
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov
- Aczone 7.5% Gel Now Approved Down to Age 9https://practicaldermatology.com/news/aczone-75-gel-now-approved-down-to-age-9/2460144/The FDA has approved the expanded indication for Almirall’s Aczone® 7.5% Gel to include patients aged 9-11. Aczone 7.5% Gel was previously approved in February 2016 to treat inflammatory and non-inflammatory acne in patients 12 and older. The expanded approval was based
- FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-juvederm-voluma-xc-for-mid-face-injection-via-cannula/2460137/Allergan’s Juvéderm Voluma XC is now U.S. Food and Drug Administration (FDA)-approved for cheek augmentation in the mid-face in adults over 21 with a TSK Steriglide cannula. This cannula features a patented tip design with a near-tip delivery port for precise product p
- Psoriasis Therapy Linked to Reduced Coronary Inflammationhttps://practicaldermatology.com/news/psoriasis-therapy-linked-to-reduced-coronary-inflammation/2460112/Anti-inflammatory biologic therapies used to treat moderate to severe psoriasis can significantly reduce coronary inflammation in patients with the chronic skin condition. Scientists said the findings are particularly notable because of the use of a novel imaging biomarker, the perivascular fat a